Moderna surges after late-stage melanoma vaccine results
Moderna (MRNA) is up more than 90% this morning following an experimental cancer vaccine jointly developed with Merck that showed promise in a late-stage melanoma trial.
MRNA Moderna is surging over 90% this morning after the company's experimental cancer vaccine, jointly developed with Merck, showed promise in a late-stage trial focused on melanoma.
Cracked the holy Grail.
While there's heavy short interest in Moderna, this vaccine is one reason why I said last month the stock was finally investable again.
Merck shares are up almost 7%.
Really bullish. - per Cramer Investing Club Newsletter